The Genome Sciences and Cancer Division provides a well-integrated research and training environment in which the latest genomic, molecular, biochemical and computational approaches are combined with genetic models to connect genotype with phenotype, understand disease pathologies and develop new treatments. Some key research directions are:

  • Unmask information latent in the genome that controls cell fate during development to better understand human disease.
  • Probe the regulatory architecture of genomes, including features of the epigenome, chromatin, and higher-order chromosomal structure.
  • Decipher the RNA-code, with emphasis on the dynamic ribonucleoprotein interactions essential for all life.
  • Elucidate intra- and extracellular signalling networks in the context of normal organismic function and diseases of development and malignancy.
  • Employ gene editing technology to develop pre-clinical genetic models (Drosophila, mice and human organoids) for cancer and related diseases.
  • Generate therapeutics targeting epigenetic modifiers, RNA networks, transcriptional regulators, and ribosome biogenesis, and exploiting tumour immunology.
  • Understand the contribution of the vasculature, platelets and neutrophils to disease, including metastasis and thrombosis.

The Genome Sciences and Cancer Division is headed by Professor Leonie Quinn who also lead the Brain Cancer Discovery Group and the Canberra Brain Cancer Collaborative.